The Effects of Aspirin in Gestation and Reproduction

Inclusion Criteria

• •Women experiencing one or two pregnancy losses at any point in gestation in the past that were not elective termination(s). At least one of these losses must be well documented by one of the following:
• •* Sonogram demonstrating anembryonic loss, embryonic loss or fetal death.
• •* Histologic confirmation of products of conception that were spontaneously passed per vagina or surgically obtained.
• •* Hospital records of fetus delivery.
• •* Late menses and positive serum hCG or positive urine hCG documented by hospital or clinic records followed by either a negative hospital/clinic pregnancy test or a decline in urinary hCG level over 3 days.
• •* Home pregnancy tests without hCG confirmation from a healthcare provider (either serum or urine) will not be accepted.
• •No more than 5 pregnancies in total including the pregnancy loss(es).\*
• •Up to two prior pregnancies that did not end in a loss.\*
• •\*Women may have up to two pregnancies beyond 20 weeks that were not losses, two spontaneous pregnancy losses at any time in the past, and up to one therapeutic or elective termination (two therapeutic or elective terminations if no other pregnancies). Ectopic and molar pregnancies would, for the purpose of enrollment, be considered in the same category as therapeutic termination pregnancies. Women with more than two live births or those with more than two losses, regardless of the week of gestation of the loss, are excluded.
• •Presence of intact tubes (both), ovaries (both), and uterus.
• •Between 18 and 40 years of age at time of baseline visit.
• •Regular menstrual periods between 21 - 42 days in length (within the last 12 months). Regular menstrual periods are defined as no more than an 8-day difference between the woman's shortest and longest cycle.
• •No more than one missed menses in the past 12 months (other than those missed due to pregnancy or breastfeeding).
• •Actively trying to conceive with a male partner and not using contraception by the baseline visit.
• •Not currently pregnant at the baseline or randomization visits.
• •Ability and willingness to give informed consent.
• •Willingness to be randomized and to take daily study pills for 6 months to a possible 15 months
• •Exclusions Criteria:
• •Known allergies to aspirin or non-steroidal anti-inflammatory agents.
• •Clinical indication for anticoagulant therapy. These include prior or current thrombosis, antiphospholipid syndrome (APS) or known major thrombophilia.
• •Clinical indication for chronic use of NSAIDs such as rheumatoid arthritis.
• •Indication for additional folic acid supplementation, such as prior infant with neural tube defect (NTD), seizure disorder.
• •Medical contraindication to aspirin therapy. These include uncontrolled asthma, nasal polyps, bleeding disorders, or history of gastrointestinal ulcer.